A B S T R A C r Daily oral administration of 1,25-dihvdroxycholecalciferol to vitamin D-deficient rats increases the rate of disappearance of [3H]1,25-dihydroxycholecalciferol and increases the rate of appearance of metabolites both less polar and more polar than 1,25-dihydroxycholecalciferol in the intestine, bone, liver, kidney, plasma, and muscle. Since 1,25-dihydroxycholecalciferol is believed to be the metabolically active form of vitamin D in the stimulation of intestinal calcium transport and bone calcium mobilization, these results provide an explanation for the fact that daily oral administration of 1,25-dihydroxycholecalciferol is relatively ineffective in the maintenance of serum calcium and in the calcification of bone in rats.
INTRODUCTION
It is now generally accepted that vitamin D must be converted to more active forms in order to carry out its physiological actions in intestine and bone. The existence of these active metabolites of vitamin D was originally demonstrated by Lund and DeLuca in 1966 (1) . Two years later, the first of these metabolites was isolated from plasma and identified as 25-hydroxycholecalciferol (25-OHD3)1 (2) . This compound, which is produced in the liver from vitamin D3 (3, 4) , is not the final active form of vitamin D3. A more polar metabolite appears in the intestine from 25-OHD3 (5-7) and has recently been isolated and identified as 1,25-dihydroxycholecalciferol (1, 25-[OH]2D3) (8, 9) . Confirmation of this This work was supported by grants from the National Institutes of Health nos. AM-14881, AM-15512, and GM-00236 BCH.
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Abbreviations used in this paper: 25-OHD3, 25-hydroxycholecalciferol; 1,25-(OH) 2Ds, 1,25-dihydroxycholecalciferol. structure using a partially purified preparation from kidney homogenate was independently achieved by Lawson, Fraser, Kodicek, Morris, and Williams (10) .
When given intravenously as a single-pulse dose, 1,25-(OH)2D3 has been shown to act more rapidly than 25-OHD3 in stimulating intestinal calcium transport (11, 12) and in activating the bone calcium mobilization system (12, 13) . Although more active than 25-OHD3 in the intestinal calcium transport system (11-13), 1,25-(OH)2D3 was equally as active as 25-OHD3 in the bone calcium mobilization response and was much less active in the cure of rickets in rats (12) .
That it is indeed 1,25-(OH)2D3 that is responsible for the observed physiological effects has been shown in a number of experiments. Fraser and Kodicek (14) have demonstrated that the 1,25-(OH)2D3 is produced from 25-OHD3 in the kidney, an observation confirmed by Gray, Boyle, and DeLuca (15) . It therefore logically follows that in nephrectomized rats, physiological doses of 1,25-(OH)2D3 but not 25-OHD3 will stimulate intestinal absorption of calcium (16) and the mobilization of calcium from bone (17) . Similarly, since the conversion of 25-OHD3 to 1,25-(OH)2D3 is blocked by previous treatment with actinomycin D (18) , rats treated with actinomycin D show a normal intestinal response to 1,25-(OH)2D3 but not to . In fetal bone tissue culture, 1,25-(OH)2D3 will cause bone calcium mobilization at much lower levels than 25-OHD3 (20) . Finally, at the time when 1,25-(OH)2D1 is producing its maximal intestinal calcium transport response, it is the only detectable metabolite in the intestine of chicks (21) and the major metabolite in the intestine of rats (22) . Similar results have been obtained with the bone calcium mobilization system (22 (25) (247,000 dpm/62.5 pmol) using the kidney homogenate method originally described by Fraser and Kodicek (14) and modified by Boyle and coworkers (16) (170 dpm/60 pmol) every 12 h for 6 days was administered in 0.1 ml of the oil by stomach tube to each of the nine rats in the third group. On the 7th day, three of the rats in this group received orally 0.1 ml of oil as a control while the remaining six rats were given 58 pmol of high specific activity
[3H]1,25-(OH)2D3 in 0.1 ml of oil. All of the rats in the three groups were killed 7 h after their last dose. The plasma, intestine, bone, liver, kidney, and muscle of all the rats but those in the control group were collected. The individual tissues from all rats in a group were pooled. These tissues were then counted, extracted with chloroformmethanol, and the lipid extracts chromatographed on Sephadex LH-20 columns (chloroform: Skellysolve B: methanol, 75: 23: 2, vol/vol) as described previously (22) . For the control group, the radioactivity present in the tissues was determined by combustion in a Packard Tri-Carb Sample Oxidizer, (model 305, Packard Instrument Co., Inc., Downers Grove, Ill.) before counting the sample.
To determine the biological activity of 1,25-(OH)2D3 under these conditions rats were again divided into three groups. To each of five rats in one group was given intravenously 60 pmol of low specific activity 1,25-(OH) 2D3.
Five additional rats received intravenously 0.05 ml 95% ethanol only. A second group of six rats received an oral dose of 64 pmol of 1,25-(OH)2D8 in 0.1 mol of oil every 12 h for 7 days. Similarly, an oral dose consisting of 0.1 ml of oil only was given to each of 10 rats every 12 h for 6 days. On the 7th day five of these rats were orally given 64 pmol of 1,25-(OH)2Ds in 0.1 ml of oil while the remaining five rats received 0.1 ml of oil only. All the rats in the three groups were killed 7 h after their last treatment. Their serum calcium and intestinal calcium transport ratios were determined as described previously (22) .
RESULTS
The biological activity of 1,25-(OH)2Ds after various methods of administration of the metabolite to vitamin D-deficient rats is shown in Table I . When examining the bone calcium mobilization response, as determined by the serum calcium values, a single intravenous dose is more effective than a single oral dose, which in turn is more effective than repeated oral doses. The intestinal calcium transport response shows no difference after a single intravenous or oral dose of 1,25-(OH)2D3. With repeated oral doses of 1,25-(OH)2Ds a slightly lower response is noted; however, this decreased response is not significantly different from the response observed after a single oral dose of 1,25-(OH)2Ds to the rats.
The distribution of radioactivity among the various tissues studied after administration of the high specific activity 1,25-(OH)2Ds to vitamin D-deficient rats or deficient rats pretreated orally with 1,25-(OH)I)2Ds is shown in apparent that there is essentially no radioactivity in the LH-20 columns the concentration of 1,25-(OH)2D3 in rats due to the pretreatment with the lowv specific activity these tissues could be calculated (Table III) . It is evi-1,25-(OH)2D3. dent that the concentration of 1,25-(OH)2D3 appearing When the radioactivity appearing in the lipid extracts in the tissues is lower in the rats given the single oral of the various tissues was chromatographed on Sephadex dose when compared with those given the intravenous were killed 7 h after their last dose and the radioactivity present in the tissues determined as described in the text. The rats were treated as described in Table II . The tissues were extracted with chloroform-methanol and the lipid extracts applied to Sephadex LH-20 columns (chloroform: Skellysolve B :methanol, 75:23:2, vol/vot).
dose. This decrease becomes more pronounced in the rats pretreated with 1,25-(OH)sDs.
When the metabolism of [IH]1,25-(OH)ODa is examined (Table IV) a number of interesting observations can be made. First a comparison between the intravenously dosed animals and the animals given the single oral dose shows a decrease in the percent of the homogenate radioactivity appearing as 1,25-(OH)2Da and an increase in the water-soluble metabolites in the kidney, plasma, liver, and muscle of the orally dosed rats. This change in the metabolite picture is also noted when the tissues from the pretreated rats are examined. A second striking change in those animals given the pretreatment of 1,25-(OH)2DI is found in the bone and muscle. In these tissues 45 and 31% of the homogenate radioactivity appears in two peaks less polar than 1,25-(OH) 2Ds compared with 0-4% in the intravenously and orally dosed rats. Finally, the tissues of the pretreated rats show a peak more polar than 1,25-(OH)2Ds which accounts for 6-14% of the homogenate radioactivity. In the intravenously and single orally dosed rats this same peak represents only 0-5% of the total homogenate radioactivity. (12) produced the apparent conflict that after an intravenous dose of 1,25- The rats were treated as described in Previous experiments hav-e demonstrated that after administration of 1,25-(OH)2D3 to rats it is the 1,25-(OH)2D3 itself which is responsible for the stimulation of the intestinal calcium transport system and the bone calcium mobilization response, both of which are needed to raise the serum calcium and phosphorus to a sufficient level for calcification to occur. If the 1,25-(OH)2Ds is rapidly degraded in the intestine to other compounds the effective lifetime of 1,25-(OH)2D3 in the body would be markedly shortened. That such an action may be occurring is suggested by the results in Tables III and IV where after pretreatment of rats with 1,25-(OH)2D3, the concentration of 1,25-(OH)2D3 in the tissues due to the last administered dose is decreased and the amount of the metabolites of 1,25-(OH) 2D3 is increased when compared with rats given a single oral or intravenous dose. These data also explain the previous observation that vitamin D-deficient rats treated orally with 1,25-(OH)2D3 over a period of days behave in many respects like untreated vitamin D-deficient rats (23) . In contrast to this, vitamin-D-deficient rats given daily oral doses of either vitamin D3 or 25-OHD3 show a marked stimulation in growth, serum calcium levels, and bone calcification. It therefore appears likely that 1,25-(OH ) 2D3 stimulates a system or systems in intestine wNhich rapidly metabolizes the 1.25-(OH) 2D3. Thus when oral doses of 1,25-(OH)2D3 are given to such rats, little of it survives passage through the intestine, thus reducing markedly its physiological effects.
DISCUSSION Earlier results of Omdahl et al
It is interesting to note that the concentration of 1.25-(OH)2Ds in the intestine of the pretreated animals is still at a high enough level to stimulate the intestinal calcium transport response. However, even with calcium entering the plasma through the intestine, bone calcification still does not occur suggesting perhaps, among other things, the further involvement of 1,25-(OH)2D3 in the calcification process. 
